Product Description
A miniaturized drug conjugate composed of a peptide analog of somatostatin that targets the somatostatin receptor 2 (SSTR2) and is conjugated, through a cleavable linker, to the microtubule-binding cytotoxic maytansinoid DM1 (mertansine), with potential anti-tumor activity.
Mechanisms of Action: SSTR Modulator
Novel Mechanism: Yes
Modality: Peptide/Protein
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Tarveda
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Neuroendocrine Carcinoma|Small Cell Lung Cancer|Neuroendocrine Tumors|Large Cell Carcinoma|Pancreatic Cancer|Thymus Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| PEN-221-001 | P2 |
Completed |
Neuroendocrine Tumors|Small Cell Lung Cancer|Neuroendocrine Carcinoma |
2020-07-31 |
|
| Phase 1/2a to assess PEN-221 in somatostatin receptor 2 expressing advanced cancers | P2 |
Unknown status |
Pancreatic Cancer|Thymus Cancer|Large Cell Carcinoma|Neuroendocrine Carcinoma|Small Cell Lung Cancer |
2019-02-09 |